ESR1 and cancer: The genetic alterations in T47D and MCF7 cancer cells with ESR1 mutations have resulted in the resistance to fulvestrant, raloxifene, and 4-Hydroxytamoxifen (4-OHT) drugs under in vitro conditions [76].